A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carboplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Pegfilgrastim
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use

07 Oct 2022 Planned End Date changed from 30 Jun 2023 to 1 Sep 2023.
30 Jul 2021 Primary endpoint has been met. (The completion rate of chemotherapy in combination with chemoradiation), as per Results published in the Clinical Cancer Research
30 Jul 2021 Results assesing relationship between ctDNA and clinical outcomes and feasiblity and rate of pCR for neoadjuvant FOLFIRINOX followed by chemoradiation, published in the Clinical Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com